Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
David B. Page(Providence Portland Medical Center), Sylvia Adams(NYU Langone Health), Alexandra Thomas(Atrium Health Wake Forest Baptist), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Kevin Kalinsky(Emory University), Benjamin G. Vincent(University of North Carolina at Chapel Hill), Margaret E. Gatti‐Mays(National Cancer Institute), Elizabeth A. Mittendorf(Dana-Farber Brigham Cancer Center), Mary L. Disis(University of Washington), Julia White(The Ohio State University), Steven J. Chmura(University of Chicago), Mei‐Yin C. Polley(Mayo Clinic in Arizona), David W. Cescon(Princess Margaret Cancer Centre), Harry D. Bear(Virginia Commonwealth University), James L. Gulley(National Institutes of Health), Erin F. Cobain(University of Michigan), Sofia R. Gameiro(National Institutes of Health), Joseph A. Sparano(Albert Einstein College of Medicine), Justin M. Balko(Vanderbilt University Medical Center), Rita Nanda(University of Chicago), Sangeetha Prabhakaran(University of New Mexico), Heather L. McArthur(Cedars-Sinai Medical Center)
Cited by 86
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
|Journal of Clinical Oncology|2014|1.3k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k